Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Avantis US Small Cap Value ETF

Vanguard Total Stock Mkt Idx Inv

BlackRock Advantage Small Cap Core Instl

Schwab US Small-Cap ETF™

Allspring Small Company Val

Federated Hermes MDT SCC Institutional

Federated Hermes MDT Small Cap Core IS

Allspring Small Company Value Admin

Vanguard Health Care ETF

DFA US Targeted Value I

FullerThaler Behavioral Micro-Cap Core

Xtrackers S&P 500 Swap ETF 1C

Schwab Fundamental U.S. Small CompanyETF

SPDR® S&P Biotech ETF

Invesco FTSE RAFI US 1500 Small-Mid ETF

Vanguard Institutional Extnd Mkt Idx Tr

Vanguard Strategic Equity Inv

Palisade Small Cap Core Equity

Schwab Fundamental US Small Company Idx

Fidelity Extended Market Index

BlackRock Inc

Vanguard Group Inc

Millennium Management LLC

D. E. Shaw & Co LP

Palisade Capital Management LLc

Two Sigma Investments LLC

Assenagon Asset Management SA

Dimensional Fund Advisors, Inc.

Geode Capital Management, LLC

Two Sigma Advisers, LLC

Renaissance Technologies Corp

Jane Street Group LLC

Marshall Wace Asset Management Ltd

Charles Schwab Investment Management Inc

State Street Corp

American Century Companies Inc

Morgan Stanley - Brokerage Accounts

Oak Hill Advisors LP

Amvescap Plc.

Connor Clark & Lunn Inv Mgmt Ltd

Emergent Biosolutions Inc

Mr. Richard S. Lindahl M.B.A.

Executive VP, CFO & Treasurer

Ms. Coleen  Glessner

Executive Vice President of Global Quality and Ethics & Compliance

Mr. Paul A. Williams

Senior Vice President of Products Business

Mr. Joseph C. Papa Jr.

CEO, President & Director

Ms. Jessica  Perl

Senior VP, Corporate Secretary & General Counsel

Ms. Michelle  Pepin

Senior VP & Chief Human Resource Officer

Ms. Stephanie  Duatschek

Senior VP, Chief Strategy & Transformation Officer

Mr. William  Hartzel

Senior Vice President of Manufacturing & Bioservices

Mr. Simon C. Lowry M.D.

Chief Medical Officer & Head of Research and Development

EBS's next earnings is on March 4, 2025 (Before Market Open)

EBS's latest dividend is 1.855 USD on August 1, 2016

Emergent Biosolutions Inc (EBS) Stock Analysis, Discussion Forum and Financial Metrics - NYSE Exchange

Emergent Biosolutions Inc (EBS) Earnings Report Date and History | NYSE

EBS's next earnings is on March 4, 2025 (Before Market Open)

When is the earnings report for EBS?

EBS Earnings History

EBS's latest dividend is 1.855 USD on August 1, 2016

EBS Stock Discussion Forum and Message Board

News for NYSE: EBS